Language selection

Search

Patent 2327169 Summary

Third-party information liability

Some of the information on this Web page has been provided by external sources. The Government of Canada is not responsible for the accuracy, reliability or currency of the information supplied by external sources. Users wishing to rely upon this information should consult directly with the source of the information. Content provided by external sources is not subject to official languages, privacy and accessibility requirements.

Claims and Abstract availability

Any discrepancies in the text and image of the Claims and Abstract are due to differing posting times. Text of the Claims and Abstract are posted:

  • At the time the application is open to public inspection;
  • At the time of issue of the patent (grant).
(12) Patent Application: (11) CA 2327169
(54) English Title: SOLID PHASE TEST FOR ENDOTOXIN
(54) French Title: ESSAI EN PHASE SOLIDE POUR DETECTER L'ENDOTOXINE
Status: Deemed Abandoned and Beyond the Period of Reinstatement - Pending Response to Notice of Disregarded Communication
Bibliographic Data
(51) International Patent Classification (IPC):
  • G01N 33/579 (2006.01)
  • G01N 33/543 (2006.01)
  • G01N 33/569 (2006.01)
(72) Inventors :
  • MAHIOUT, AREZKI (United Kingdom)
(73) Owners :
  • ALLIED THERAPEUTICS LIMITED
(71) Applicants :
  • ALLIED THERAPEUTICS LIMITED (United Kingdom)
(74) Agent: SMART & BIGGAR LP
(74) Associate agent:
(45) Issued:
(86) PCT Filing Date: 1999-04-09
(87) Open to Public Inspection: 1999-10-21
Availability of licence: N/A
Dedicated to the Public: N/A
(25) Language of filing: English

Patent Cooperation Treaty (PCT): Yes
(86) PCT Filing Number: PCT/GB1999/001099
(87) International Publication Number: GB1999001099
(85) National Entry: 2000-09-29

(30) Application Priority Data:
Application No. Country/Territory Date
9807814.0 (United Kingdom) 1998-04-09

Abstracts

English Abstract


A solid phase apparatus, for detection of endotoxin in a liquid sample using
reagents located within solid support material, comprises endotoxin sensitive
reagent and buffer components. When a liquid sample containing endotoxin is
applied to the apparatus the endotoxin sensitive reagent reacts with the
endotoxin to form at least one product, and following contact of the at least
one product with buffer components, an endotoxin indicator is formed. Also
disclosed are a method and a kit to test for endotoxin.


French Abstract

L'invention concerne un appareil à phase solide permettant de détecter l'endotoxine dans un échantillon liquide, à l'aide de réactifs situés à l'intérieur d'un support solide, cet appareil comprenant un réactif sensible à l'endotoxine ainsi que des composants tampons. Lorsque l'on applique à cet appareil un échantillon liquide contenant ladite endotoxine, le réactif sensible à l'endotoxine réagit avec cette dernière de manière à former au moins un produit, le contact de ce produit et desdits composants tampons permettant par ailleurs de former un indicateur d'endotoxine. L'invention concerne également une méthode et un kit d'essai permettant de détecter l'endotoxine.

Claims

Note: Claims are shown in the official language in which they were submitted.


-15-
CLAIMS
7. Solid phase apparatus, for detection of endotoxin in a liquid sample
using-reagents located within solid support material, comprising the reagents:
endotoxin sensitive reagent; and
buffer components;
wherein whet a liquid sample containing endotoxin is applied to the
apparatus the endotoxin sensitive reagent reacts with the endotoxin to form at
least one product, and following contact of the at least one product with
buffer
components an endotoxin indicator is formed.
2. Solid phase apparatus according to Claim 9 further comprising a colour
developer, which reads with the endotoxin indicator to form a coloured
product.
3. Solid phase apparatus according to Claim 1 or 2 wherein the reagents are
differentially located within portions of the solid support material, and
wherein the
apparatus comprises:
an application portion to receive a liquid sample, and containing endotoxin
sensitive reagents comprising endotoxin sensitive factor aid a first
chromogenic substrate, and being in communication with a buffer portion;
the buffer portion containing buffer components, end being in
communication with an indicator portion; and
the indicator portion optionally containing a colour developer or being
adapted to receive application of a colour developer by a user
wherein in use when a liquid sample containing endotoxin is applied to the
application portion, endotoxin reacts with endotoxin sensitive factor to form
a
product which in turn reacts with the first chromogenic substrate to form a
second
chromogenic substrate, and contact of the second chromogenic substrate with
buffet components forms an endotoxin indicator.

-16-
4. Solid phase apparatus according to Claim 3 wherein the application portion
comprises:
a first portion containing an endotoxin sensitive factor, in communication
with
a second portion containing a first chromogenic substrate, in communication
with the buffer portion.
5. Solid phase apparatus according to Claim 3 or 4 wherein the buffer portion
comprises:
a third portion containing first buffer components, in communication with
a fourth portion containing second buffer components, in communication
with the indicator portion, whereby in use contact of the second
chromogenic substrate with the first and then the second buffer components
results in formation of the endotoxin indicator.
6. Solid phase apparatus according to Claim 3, 4 or 5 wherein the indicator
portion is substantially free of solute capable of altering pH.
7. Solid phase apparatus according to any of Claims 1-6 for the detection of
endotoxin in a liquid sample comprising a solid support in the form of a test
dipstick, a flat sheet or a cylindrical capillary tube wherein said solid
support is
selected from chromatographic papers, silica nitrocellulose, hydrophillic
polymer,
dextran, and glass fibres.
8. Solid phase apparatus according to any previous claim in the form of a said
test strip which comprises several portions made with hydrophillic matrix from
which .beta.-glucans have previously been extracted with a solvent system;
9. Solid phase apparatus according to Claim 8 wherein the test strip is
constructed in a flat sheet form, said portions are constructed in a plane
form to
permit capillary flow, between respective portions.

-17-
10. Solid phase apparatus according to any previous claim wherein the solid
support material is mounted in a closed and pyrogen free transparent casting
module to achieve pyrogen free manipulation.
11. Solid phase apparatus according to Claim 10, wherein the said transparent
casting module can be opened at the bottom to permit contact with the sample
or
can be placed in a sample reservoir and can be opened at the top to permit
contact
with chemical reactants.
12. Solid phase apparatus according to any previous claim wherein the colour
developer is N1-napthylethylenediamine.
13. Solid phase apparatus according to any previous claim wherein the
endotoxin
sensitive factor a limulus amoebocyte lysate or other factors which react with
endotoxin to produce coagulin.
74. Solid phase apparatus according to any previous claim wherein the first
chromogenic substrata is t-butoxycarbonyl-leucyl-glycyl-arginine-
paranitroanilide
(Boc-Leu-Gly-Arg-pNA) and paranitroanilide is the second chromogenic
substrate.
15. Solid phase apparatus according to Claim 14, wherein the endotoxin
indicator is p-nitroaniline.
16. Solid phase apparatus according to any previous claim wherein the buffer
components contain hydrochloride and sodium nitrite ions.
17. Solid phase apparatus according to Claim 16, wherein the buffer components
contain hydrochloride and ammonium ions.
18. Solid phase apparatus according to any previous claim wherein the
indicator
portion is a neutral portion.

-18-
19. Solid phase apparatus according to any previous claim wherein contact on
the second chromogenic substrate with buffer components converts it to a
diazonium salt.
20. Solid phase apparatus according to Claim 19, wherein which p-nitroaniline
is derivatized to N1-napthylethylenediamine.
21. Solid phase apparatus according to Claim 20, wherein the indicator portion
is changed to a highly visible red colour when a drop of a solution containing
N1-naphtylethylenediamine is added to form a diazoamino of a highly visible
red colour.
22. Solid phase apparatus according to Claim 20, wherein the indicator portion
contains a solid support and N1-naphtylethylenediamine to form a diazoamino of
a highly visible red colour.
23. A method of assaying for the presence of endotoxin in a liquid sample,
comprising
combining a test amount of the sample with reagents in a first region of solid
phase support materia to form at least one product:
allowing the one or more products to flow through a second region of solid
support material containing buffer components thereby to convert the at least
one
product into endotoxin indicator; and
testing for the presence of the endotoxin indicator.
24. A method according to Claim 23 wherein endotoxin indicator is coloured.
25. A method according to Claim 23 further comprising reacting, in a region of
solid support material, the endotoxin indicator with a colour developer to
form a
coloured product.
26. A method according to any of Claims 23 to 25 comprising heating the
support material to activate the reagents.

-19-
27. A method according to any of Claims 23 to 26 comprising measuring the
intensity of the coloration of the endotoxin indicator to determine
concentration of
endotoxin.
28. A kit for testing for the presence of endotoxin in a liquid sample,
comprising
at least two solid phase apparatus according to any of claims 1 to 22, wherein
the
at least two apparatus have different sensitivities to endotoxin.
29. A kit according to Claim 28 comprising a plurality of solid phase
apparatus
of different sensitivities, to endotoxin for quantitative determination of
endotoxin in
a liquid sample.
30. Use of solid phase material containing buffer components in manufacture of
solid phase apparatus or testing for the presence of endotoxin in a liquid
sample.
37. Use of solid phase material containing endotoxin sensitive reagent in
manufacture of solid phase apparatus for testing for the presence of endotoxin
in
a liquid sample.

Description

Note: Descriptions are shown in the official language in which they were submitted.


10-JGr-GKJrJYJ LO~Gl I'IHIfITJ 6 JhlUlKt i'JGIO -ftiJb YJI~I'Jl h'.1~~1~J1~
CA 02327169 2000-09-29
wo ms332~ rcrrcs9sro~o99
-1-
S()L1D PHASE TEST FOR ~NDOTOXIN
" This invention relates to a solid phase test for endotoxin, in particular.a
test such
as in a flat sheet or in capillary form for the detection of endotoxin in
aqueous
solutions. More particularly the invention relates to a direct solid phase
chromogenic assay, which permits a quick biochemical identification of
endotoxin
and is sensitive to pico~3ram endotoxin~amounts.
There is a high demand for testing for contamination of solutions and
biological
fluids in medicine and iriotechnologies; for instance, the quality of water
used for
the dilution of solute concentrates for hemodialysis. Specifically, there is a
need
for pyrogen free water to make dialysate, and far monitoring of the dialysate
in the
dialysis machine itself in centres or at home or other non-laboratory
settings. (n
this respect, the production of sterile and pyrogen free dialysate needs a
pyrogen
control method which will give a 'yes" or "contaminated" result. Endotoxin,~ a
potent pyrogen specifically from gram-negative bacterial cell wall components,
is
one of the mast known key contaminants. Measurements of endotoxin are today
used as the major safe-y parameter of infusions and fluids in general, drugs
and
devices, in the pharma:ology and food industry.. The most available method to
qualitatively and quanti-:atively detect endotoxin in biological or aqueous
solutions
is based on the limulus amoebocyte lysate (LAL) test known in the art.
The LAL test was dis~:overed in 196ø by Levin and Bang' . Horseshoe crab
(limulus) amoebocyte lysate provokes together with endotoxin from gram-
negative
bacteria a gelatination induced by a stepwise activation of several
coagulation
factors contained in tile lysate. An assay comprising the extract (lysate) of
horseshoe crab blood cell (amoebocyte) to induce this ge(atination in a
reagent
glass as a liquid phasE system is welt known as a method and it is called the
limulus test. The application of the LAL to measure endvtoxin involves the
gelatination of the sample (gelation method, turbidimetry assay) in the
reagent
glass or a more sen;,itive method based on a chromogenic substrate and
measurement by optics absorption. Today different LAL from horseshoe crab I
are
SUBSTrTUT>w SHEET (RUE~E 26)

sa-5tr-~t~ m: ~~ MH I HY5 7S ShIU 1 Kt d'~I~ ~rase dem r. tai
CA 02327169 2000-09-29
WD 99153322 , PCT1GB991Q1099
-2-
commercialized through the world: Limulus Polyplfemus, Tchypleus tridendatrrs,
Tachypleus gigas and Carcinoscorpius rotundicauda.
r.'
Al! commercialized LAL testing methods based on a chromogenic substrate are
liquid-phase assays. Th~. principle is that in a reagent glass containing a
lysate and
sample, bacterial sndo~toxin contained in the sample initiates activation of a
cascade of serine protease (Factor 8, Factor C, Proclotting enzyme, Coagulin)
enzymes in LAL that cl~:ave the end product coagulogen into a peptide coagulin
which produces clotting. The use of a synthetic chromogenic or fluorogenic
substrate increases the sensitivity of the testing and makes the
quantification of
endotoxin possible. As described by Iwanaga et al', a synthetic peptide is
used
having an amino acid sequence in common with the hydrolysis sites of
coagulogen,
namely the chromogenic substrate Boc-Leu-Gly-Arg-p-nitraanilide IpNA~ or the
fluoro-genie substrate Box-Leu-Gly-Arg-4-methylcoumaryf-7-amide. !n the
presence
of LAL and endotoxin, the colourless substrate is rapidly cleaved to form the
chromophore p-nitroaniline or the fiuorogenic 4-methylcoumaryl-7-amide.
There are today increasing improvements in the accuracy and, sensitivity of
liquid
phase assays: in US patent 5 605 806, S. Tanaka and H. Tamura proposed a LAL
and an antibody to ne~~traiize the false positive results due to (1 -> 3)-Q-
glucan.
Shigenori et a! proposed the use of factor G activation to resolve the same
problem
(US patent 5.641,643?. Besides the liquid phase reaction systems, a method for
lysate immobilization tc~ wells of a polystyrene microplate has been
published. In
US patent 5,550,30, Tanaka disclosed a quantitative kit for endotoxin
determination which comprises an insoluble carrier vn which is immobilized an
endotoxin-sensitive factor derived from a limulus amoebocyte which
specifically
reacts with endotoxin Yr'rthout reacting with 13-glucan. The test system
involves the
indication of endotoxi~ when colouring occurs in the liquid phase.
Quick and simple testing for endotoxin is important in a number of
circumstances,
including when changilg the dialysis machine, or monitoring tap water. It is
also
desirable to determine endotoxin levels of the fluids in a laboratory-setting.
The
SUBSTITUTE SHEET (RULE 26)

1a-5tr-~~d lb: ~~ f9H ~ hirb 2~ 51~u1Kt nee rrx~e~ eiemi r. no.,~r~
CA 02327169 2000-09-29
w0 99I533Z2 PCTIGB99101099
-3-
degree of contaminati~~n of water and dialysate fluids falls into several
categories,
but in all cases it is de~.irable to monitor endotoxin present in the fluid on
a frequent
-' basis. A simple and quick method for determining qualitatively endotoxin in
a-test
solution is thus much sought in the art.
The present mventio.~ provides an analytical test strip for the detection of
endotoxin in aqueous .solutions in which the strip is wetted at the bottom
with the
sample. After a certain period of time, until the sample flows from the bottom
to
the top, an indicator is added at the top, to develop a red colour which is
indicative
for the presence or the absence of endotoxin in the sample.
Using a technique of a solid phase chromogenic substrate assay, the present
invention involves an improvement to a quick test strip for the detection of
endotoxin. The test strip provides a dry analytical element for endotoxin
which
comprises an absorbent carrier divided in four portions impregnated with: 1 ).
a
reagent system of lim~:lus factors; 2) synthetic chromogenic substrate
derivatized
with' p-nitroaniline; .3) .3 buffer system containing chloride acid and sodium
nitrite;
41 a buffer system containing chloride acid and ammonium. The test afro
includes
a solution containing 111-naphtylethylenediamine which .is added at the top of
the
_ test trip to develop a coloration by coupling the derivatized p-NA- to ~N1-
napthylethylenediamine as positive results.
T'he present invention provides apparatus and method as,defined in the claims,
in
particular an analysis method comprising applying a aqueous sample solution to
the
bottom of the described dry analytical element to react with endotoxin, and
determining coloratioi on the top of the dry element by coupling N1-
napthylethylenediamine. The present invention also provides an endotoxin kit
using
- the above described dry analytical element.
A further object of this; invention is to provide a method for preparing the
above
mentioned dry analytical element andlor the portions of the dry analytical
element
for preparing the above described endotoxin test strip.
SUBSTITUTl; SHEET (RULE 26)

18-SEP-2000 16~23 MHTHYS 8 SQUIRE 020 ?830 0001 P.0?/30
CA 02327169 2000-09-29
WO 99153322 - PCTIGB99101099
The method involved in the invention is a direct solid phase chromogenic
caiorimetrical detection. Four supports are arranged successively in the same
alignment to achieve << flow communi6ation with each other. The supports are '
-
mounted in a closed arid pyrogen free casting module, The test strip comprises
a
solid support having four portions (at least three portions) being in flow
communication with ~:ach other whereby reaction products can flow from one
portion to the next. The solid support is preferably shaped in the form of
strip,
with the first, second, third and fourth portions being arranged on the strip
in the
same plane. The size:; of the portion may be the same or different. The
portions
are manufactured to absorb the different chemicals and dried, and attached on
the
strip in a way that flow communication occurs from one to the next.
The test strip would be submerged with the sample at the bottom to wet the
first
portion and allow liquid to flow from bottom to the top of the test strip. The
sample solution woulc start to flow by capillary action from one portion to
the next
higher portion. Thus, the reactants occurring in each portion would
be.transported
by capillary flow to th~: last portion to develop a red coloration as a
positive result.
The first portion contains a solid support and a (imulus -amaebocyte lysate or
substances containirn3 endotoxin sensitive factors which react with endotoxin
to
produce coagulin. ~he method of the immobilization of the lysate or of the
endotoxin sensitive f~sctor to the solid support are: 1 ) absorption: 2)
adsorption by
ionic forces orland hydrophobic interaction, 3y covalent binding. The
procedures
for binding the lysate in the solid support are generally known the art. The
lysate
may be the commercial available limulus amoebocyte fysate such as Limulus
Polyphemus, Tchyp~eus iridendafus, Tachypleus gigas and Carcinoscorpius
~otundicauda. Preferably a lysate without Factor G may used in order to avoid
a
positive false-reaction with i~-31-f3-WGlucan contained in the sample or in
the solid
support. A purified form of a mixture containing factors C. B and prociotting
enzymes, which react with- endotoxin to produce coagulin may also be used.
Preferably a lysate preparation known in the art without Factor G which
does.not
react with (1-3Lf3-D-Gtucan may also be used. The amount and biological
activity
SUBSTITUTE SHEEt (RUSE 25)

18-SEP-2000 16:23 MRTHYS & 5QU1RE bid 'ftiib bbdl h'.btii,5b
CA 02327169 2000-09-29
WO 99/53322 PCT/GB99I01099
-5-
of endotoxin reagents, and the material and size of the solid support
determine the
sensitivity of the test strip. Upon wetting of the solid support with the
sample,
sample.~houid react with immobilized lysate or substances containing endotoxin
factors to activate Factor and clotting enzymes. Depending upon the presence
of
endotoxin in the samples, endotoxin activates the bound lysate in the
following
reaction steps:
t1 f Endatoxin -> activated Factor C
t21 activated Factor C -~ Factor B -> activated Factor B
(3) activated Factor 8 -> Praclotting enzyme
The clotting enzyme produced through the cascade reaction by the action of
activated Factor C or proclotting enzymes is capable of hydrolysing coagu(in
or an
amide linkage of a synthetic peptide substrate at the specific sites
intermediate
between Arg and GIy ~~r intermediates between Arg and Thr.
The solid support which is- employed in this test strip is one which is
capable of
absorbing endotoxin i~rom the sample. When wetted, the sample containing
endotoxin reacts with reagents in the first portion and the reaction products
are
transported by flow to the dry region of the first support and thus to the
second
portion of the test strip. In addition, the solid support is one which is
capable of
absorbing both sample: and binder. In order to achieve a flow communication
between the portion, it is preferable to use an hydrophillic polymers solid
support.
Examples of suitable supports are chromatographic papers, nitrocellulose,
dextran
and glass fibres. Preverabiy, chromatographic hydrophobic polymers are used
though if using chrom:~tography papers, it is important to use reagents which
do
not react with -(3-gluca~, as described for example in US patent 5,550,030.
The second portion contains a solid support and a synthetic substrate. A
typical
substrate to be immobi ized in the second portion is t-butaxycarbanyl-
Ieucyl~glycyl-
SUBSTITUTE SHEET (RULE Z5j

ia-~r-~~d ib: ~4 MH I HY5 XWhIU 1 Kt. l~~b ~re,se dm r. ey~,s~o
CA 02327169 2000-09-29
WU 99153322 , PCTIGB99101099
arginine-paranitroanilide (8oc-Leu-Gly-Arg-pNA) to release paranitroani(ide.
Usable
synthetic peptides with a known detectable group are those described in EP-A-
0000063, EP-A-00113112, W079/00602, W082/02382 and US 4,188,264.
However, synthetic p~;ptide substrates for activated Factor C as well as
synthetic
peptide substrates for activated clotting enzymes in which a carboxyl group of
the
C-terminated argininE~ -is substituted with the colour-developing residue p-
nitroaniiine, p-(N,N-di~ahylamine)aniline, p-(N-ethyl-N-f~-hydroxyethyl)
aniline can
also be used. Possible methods of immobilization of the chromogenic substrate
to
the solid support ors: 1 ) absorption; 2) adsorption by ionic forces or/and
hydrophobic interacti~3n, and 3) covalent binding. Preferably, the support is
absorbed with the substrate. The solid support is typically made with the same
material as the first s~:pport and it is one which is capable of absorbing the
liquid
and reactants flowing from the first support, and which when wetted is this
way,
provides for flow and analyte by capillary attraction from the first portion,
and
through the second portion into the third portion. Upon contact with the
liquid and
reactants flowing from the first support, solution should react with
immobilized
chromogenic substrate. Like the first portion, examples of suitable supports
are
chromatographic papers, nitrocellulose, dextran and glass fibres. Preferably,
chromatographic papers are used. The s4lid support absorbed with the
ohromogenic substratE is one which is capable o~absorbing reactants flowing
from
the first support. When wetted, the so-called reactants are capable of
reacting
with the second portic,n and the reactants with the new reaction products
being
transported to the dry regions and thus to the third portion of the test
strip. The
solid , support is so manufactured (with attention to the amount of absorbed
synthetic chromogenic substrate, size of the portion, material of the solid
support)
that activated clotting ~:nzyme andlor factor B flowing from the lower portion
reacts
with substrate in the second portion and the chromophore p-nitroaniline is
cleaved.
The cleaved p-nitroaniline is then transported to the next portion.
The third portion contains a solid support and a buffer containing 1 N NCI and
0.1 % (wlv) sodium nit~ite. Preferably, to make the support; it is impregnated
with
the buffer system, dried and is made with the same material as the second
support.
SUBSTiME SHEET (RULE ?.~)

11i-5th'-~I~b 1b~~4 IhHIHYS ZS SL,lUIKt 1~~'t~ '~ti,5l~ l:)b1~1 t'.11~~,310
CA 02327169 2000-09-29
WO 99153322 PC'T'IGB99101099
.7.
When dried, the~solid support is also one which is capable of absorbing the
liquid
and the chromophore p-nitroaniline flowing from the second support, and which
when wetted is this may, provides for flow from the second portion, and
through
the third portion into the fourth portion.
The fourth portion contains a solid support and a buffer containing N HCI
containing 0.5°6 ammonium. Preferably, to make the support, it is
impregnated
with the buffer system, end dried. When absorbed with the buffer system and
dried, the solid support is also one which is capable of absorbing the liquid
and the
chromaphore p-nitroa~iline flowing from the third support, and which when
wetted
is this way, provides for flow from the third portion, and through the dried
region,
The third and fourth portions are those through which when the flowing free p-
nittoaniiine released by the action of enzymes is derivatized to its diazanium
salt,
typically formed in th,: fourth portion.
The fifth portion is a neutral portion in which a drop of 0.05 % N 1-
naphtylethylenediamine in 40-50% (v/vf is added to form a highly visible red
colour
by cQUpling of the de-ivatized p-NA to N1-napthylethylenediamine.
The test strip described in this invention can suitably be prepared from any
matrix
material through whi~:h an aqueous solution can flow by capillarity. Suitable
materials for chromatographic strips are paper, nitrocellulose and
hydrophillic
polymers. because of the presence of f3-glucan in cellulosic material, paper
is riot
usually suitable without special treatment as it induces false positive
results. In
this invention, it is desirable to use hydrophillie polymers which allow
vertical
capillary flow excluding a bibulous lateral flow such as polyethylene sheet
material.
,_ There now foNows description of specific embodiments of the present
invention,
illustrated by drawings in which:-
Fig. 1 shows a schematic representation of a capillary test strip;
SUBSTITUTE SHEET (RULE 26~

113-5th'-~t~b lb~ ~5 MH 1 HY5 X~ 5L,lUlKt 1~~4~ 'fti.5d dbl~l h'. l lii4~
CA 02327169 2000-09-29
wo 99rs33zz , rcrrc B99ro ~ 099
-e-
Fig. 2 shows .3 schematic representation of a paper test strip;
Fig. 3 shows mode of operation of a test strip;
Fig. 4 shows variation of substrate sensitivity and resulting lysate activity;
and
Fig. 5 shows ~~ quantitative test strip.
~xarnple 1: capillary test strip
As illustrated in figure 1, a glass howl capillary glass with a flat side, an
internal
dimension of 0.25 em and an external dimension of 0.2$ cm and a length of 4 cm
has been used as the casting module. For the bottom of the capillary there is
a cap
which is used as the ,;ample reservoir, whereas a second cap closes the top of
the
capillary and permits entry of chemicals for the colour reaction. The module
is
constructed in a w.~y that it remains pyrogen free. The howl module is
successively filled wi~:h dried hydrophillic porous spherical material (200-
500 ~nl,
The hyijrophillic por4~.~s polymer is in separate portions, impregnated as
follows:
Portion 1: hydrophillic polymeric powder was incubated under pyrogen free
conditions in 0.5 IU/ml (1 glml) of limulus amoebocyte lysate (Charles River-
Suizfel
Germany) until saturated absorption of the liquid was reached. After drying,
the
module has been filled to reach a height of 1 cm. 0.1 cm has then been filled
with
neutral polymeric povrder.
Portion 2; 10 ~rmo) of chromogemic substrate (t-butoxycarbonyl-ieucyl-glycyl-
arginme-paranitroanili~e) for endoxin (Pefachrome LAL Code.NR 11179-01 ISO
9001-1N29001 Penta~pharm AG BASEL CH) was diluted in 6.6 ml pyrogen free .
water. 1 g of hydrophillic polymeric material was also incubated with 1 m1
until
saturated absorption was reached. After drying the module has been filled to
reach
a height of 0.5 cm. C1.1 cm has then been filled with neutral polymeric
powder.
SUBSTITUTE SHEET (RULE 2B)

18-SEP-2000 16~25 MATHYS & SQUIRE 020 7830 0001 P.12i30
CA 02327169 2000-09-29
WO 99!53322 PCTIGB99I01099
-9-
Between portions 2 ;end 3: Tris-HC) is mixed with polymeric powder to obtain a
concentration of 0Ø5 mmol/I and inserted between portions 2 and 3 with a
height
of O.S cm. 0.1 cm has been filled ~evith neutral polymeric powder.
' ' Portion 3: Polymeric powder was submerged in a solution of 1 N HCI
containing
0.1 % (w/v) sodium nitrite, and dried. A quantity sufficient for 0.5 cm has
been
inserted into the module. 0.9 cm has been filled with neutral polymeric
powder.
Portion 4: 1 cm of polymeric powder was submerged with in solution of 1 N HCl
containing 0.5 °~ ih~'Ivl ammonium sulfate, dried and has been filled
into the
module. 0.1 cm has been filled with neutral polymeric powder.
Portion 5 : 2.5 mg of N1-naphthlethylenediamine in mixed with 0.5 cm polymeric
material.
Example 2: paper tes-: strip '
The strip can prepared from any matrix material through which the test fluid
can
vertically flow by capillarity; as illustrated in figure 2, a polystyrene
dipstick was
constructed to be fitted in a sterile battle. The active surface of the test
strip was
0.5 cm x 4.2 cm, separated every 0.5 cm between the first portion and the
third
portion with 0.5 cm x 0.2cm dry Sephadex. The active surface between the
sephadex strip was dated with Scotch adhesive transfer tape , 969 13M, USA,
5x144)
Portion 9: consisted cf 0.5cm x 0.5 cm ultra high molecular weight
polyethylene
sheet material tPorex Technologies) which was incubated for 10 min under
pyrogen
free conditions in 0.5 IUImI ( 1 glmll of limuius amoebocyte lysate (Charles
River-
Sulxfel Germany). At;er drying, it was applied to the bottom et the test
strip, A
i
neutral 0.5 cm x 0.7 :m-portion was added above the neutral sephadex.
Portion 2: consisted of 0.5cm x 0.5 cm ultra high molecular weight
polyethylene
' SUBSTITUTE SHEET (RULE 26)

18-SEP-2000 16~26 MRTHYS 8~ SQUIRE 020 7830 0001 P.13i30
' ~~ CA 02327169 2000-09-29
wo 99is33zZ
PCT~GS99lot 099
.10-
sheet material tPorex Technologies) which was spotted with 1.5 ,umollml of
Chrvmogenic substrate (t-butaxycarbonyl-leucyl-glycyl-arginine-pa-
ranitroanilide) for
~ndoxin (Pefachrome I.AL Code NR 11179-O1 ISQ 9001-7 N29001 Pentapharm AG
BASEL CH). The strip was applied lust above the neutral sephadex portion. , -
Between portions 2 and 3: consisted of 0.5em x 0.5 cm sephadex and Tris-HC( at
a concentration of 0.025 mmolh.
portion 3: consisted of a 0.5 cm x 0.5 em strip of filter paper (Schleicher &
Shuel
23 SL) which was submerged with solution of 1 N HCl containing 0.1 °~
(w!v)
sodium nitrite, dried and applied above the neutral sephadex portion.
Portion 4: consisted of a 0.5 cmx 0.5 cm strip of filter paper (Sehleicher &
Shue)
23 SL) which was submerged with in solution of 1 N HCI captaining 0.5 % (Wlv)
ammonium sulfate, dried and applied above the third portion.
Portion 5 : consisted of a 0.5 cmx 0.5 cm strip of filter paper (Schleicher &
Shuel
23 SL) applied above the fourth portion.
For both examples :he assay is carried out as follows:
1 ) add the simple to the first portion of the test strip or immerse the first
portion in the sample (example 2) or fill the reservoir with the sample
(example 1 )-
2) heat the test strip to 37 °C device to activate the reaction;
3) allow sufficient time (such as 4 min) for the sample to flow from the
bottom to tt-;e top:
4) dry the test strip by removing the sample reservoir from the bottom and
opening the bottom of the casting; and
5) for colour development, a drop of 47.5% ethanol is added, coloration
develops after drying in air.
The chemical reactions involved in each portion are described in Figure 3. In
__ ~ .........w lot tl ~ '~i~

18-5EP-2000 16~26 MRTHYS & Sf~UIRE 020 7830 0001 P.14~30
CA 02327169 2000-09-29
WO 99/53322 PGTlGB99101099
-11-
portion 1, depending upon the presence of endotoxin in the samples, clotting
enzyme is produced through the cascade reaction by the action of activated
Factor
C or prociotting enzymes. In portion 3 after the papillary flow through the
chromagenic substra~:e and in the presence of Tris-HCI, the activated clotting
enzyme andlor factor S flowing from the lower portion cleaves p-nitroaniline.
The
cleaved p-nitraanitine being transported to the third and fourth portion and
derivatized to its diazonium salt. In the fifth portion, the diazonium salt is
coupled
to N1-napthylethylenediamine to form a diazoamino of a red colour.
The assay can be performed with different sensitivities, according to the
grade of
contamination to be analyzed. (n the special application to test solutions
used in
hemadialysis therapy and according to Pharmacopoeia prescriptions, several
test
strips have been elaborated to read the minimal acceptable concentration of
endotoxin in aqueous solution (Table 1 ).
Table 1
AppGoatians SubstitutionitemodialysisDialysateWater
for on-
solution water solutionfine HDF
for
Hamvdiafiiuatlon
Lowest LPS concentration
'n l:Ulml
0.05 0.25 0.5 t
In respect to the sensitivity of the test, numerous modification can be
performed,
such as by varying the: titration of the LAL-concentration and the matrix
material
used in the first portion. By the application of high molecular weight
polyethylene
sheet material (Pore;; Technologies) and using several titrations of limulus
amoebocyte lysate varying from 0.1 to 0.5 lUlml and several matrices, for
examples 1 and 2, it is possible to prepare 3 classes of lysate
concentrations. The
method used to prepa~e the desired lysate concentration is first based on a
liquid
.I chramagenic subsuate assay in a microplate according to the LAL-test
Endochrome-K~'"' (US. License No ~ 073) except that the I.AL-concentration is
not
related to the protocol. Figure 4 illustrates the resulting absorbance due to
the
SUBS'ffTUTE SHEET (RULE 26)

18-SEP-2000 16=2? MRTHYS 8 S(~UIRE 020 9830 0001 P.15i30
CA 02327169 2000-09-29
WO 99/53322 PC"TIG 899/0!099
- 12-
variation of the f_A!_ which allow 4 classes of test-strips. Applied to the
test-strip
of example 2, it is pv~sible to prepare a test-strip especially for the
detection of
endotoxin concentration. in diaiysate-solution, for which the acceptable
firnit is ~-
prescribed to be beiour a.5 EU/m!. Detection spots for this prepared test
strip are
ihustrated in Figure 5.
suesTtn~ sHEF-r (pum zs)

lti-5th'-~lJdd 1b ~ ~'f num t a a ~u a r~~ ~~... . ........ ....... . .
CA 02327169 2000-09-29
WO 99/S33ZZ PCTfG899101099
-13-
References:
" 7 J. Levin and F.3. Bang Bult. Johns Hopkins Hospital, 115, 265.274 (1964)
2 Progress in Clinical and Biological Research, Volume 93; 'Endotoxin and
their petection with the Limulus Amoebocyte Lysate Test"; edited by Stanly
W. Watson, Jack Levin and Thomas J. Novitsky (1982); pages 7-24
3 lwanaga et al. -temostasis, Z, 1$3-199 (18781
4 J. Clin Microbio. 17, 1050-1053 11983)
Related Application Data:
1 Solid phase chromatographic immuno assay- Rosenstein-US patent
5,591,fi45 (Jar4 7, 1997)
2 Method for the detection of protein urine- Cahil et ai: US patent 5,593,895
(Jan 14, 1997)
3 Reagent for en~otoxin-specific assay- Tanak et al, US patent 5,550,030
(Aug 27 1996)
4 Test strip for blood glucose testing- Kelvin J. Philipps- US patent
5,556,761
tSep 17, 1996)
- 5 Quantitative de°_ection of analytes on immunochromatographic strip-
Ronald
G Sommer- US patent 5,569,608 (Oct 29, 1996)
6 Horses Crab arroebocyte lysate factor G activation inhibitor- Tanaka S.- US
patent 5,641,63 (Jun, 24, 1997)
SUBS'1'1TUTE SHEET (RULE Z6)

18-SEP-2000 16~27 MRTHYS & SQUIRE 020 7830 0001 P.17/30
CA 02327169 2000-09-29
WO 99153322 . PC'1'IGB99101099
-14-
7 Reagent for assaying endotoxin. Tanak S- US patent 5,605.806 (Feb 25,
1997)
8 Test articles fvr performing dry reagent prothrombin time assays Stephen E.
Zweig et al. US patent 5,418,141 (May 23, 1995)
9 Composite celil:lose nitrate membrane on polyester support- Beer et a!- US
patent 5,628,9130 (May 13, 1997)
One step-test d~:vice. Philip W. Sayies. US patent 5,591,401 Clan 7, 1997)
SU8ST1TUTE SHEET (RULE 26)

Representative Drawing
A single figure which represents the drawing illustrating the invention.
Administrative Status

2024-08-01:As part of the Next Generation Patents (NGP) transition, the Canadian Patents Database (CPD) now contains a more detailed Event History, which replicates the Event Log of our new back-office solution.

Please note that "Inactive:" events refers to events no longer in use in our new back-office solution.

For a clearer understanding of the status of the application/patent presented on this page, the site Disclaimer , as well as the definitions for Patent , Event History , Maintenance Fee  and Payment History  should be consulted.

Event History

Description Date
Application Not Reinstated by Deadline 2003-04-09
Time Limit for Reversal Expired 2003-04-09
Deemed Abandoned - Failure to Respond to Maintenance Fee Notice 2002-04-09
Letter Sent 2001-05-24
Inactive: Single transfer 2001-04-26
Inactive: Cover page published 2001-01-23
Inactive: First IPC assigned 2001-01-17
Inactive: Courtesy letter - Evidence 2001-01-16
Inactive: Notice - National entry - No RFE 2001-01-12
Application Received - PCT 2001-01-11
Application Published (Open to Public Inspection) 1999-10-21

Abandonment History

Abandonment Date Reason Reinstatement Date
2002-04-09

Maintenance Fee

The last payment was received on 2001-03-26

Note : If the full payment has not been received on or before the date indicated, a further fee may be required which may be one of the following

  • the reinstatement fee;
  • the late payment fee; or
  • additional fee to reverse deemed expiry.

Patent fees are adjusted on the 1st of January every year. The amounts above are the current amounts if received by December 31 of the current year.
Please refer to the CIPO Patent Fees web page to see all current fee amounts.

Fee History

Fee Type Anniversary Year Due Date Paid Date
Basic national fee - standard 2000-09-29
Reinstatement (national entry) 2000-09-29
MF (application, 2nd anniv.) - standard 02 2001-04-09 2001-03-26
Registration of a document 2001-04-26
Owners on Record

Note: Records showing the ownership history in alphabetical order.

Current Owners on Record
ALLIED THERAPEUTICS LIMITED
Past Owners on Record
AREZKI MAHIOUT
Past Owners that do not appear in the "Owners on Record" listing will appear in other documentation within the application.
Documents

To view selected files, please enter reCAPTCHA code :



To view images, click a link in the Document Description column (Temporarily unavailable). To download the documents, select one or more checkboxes in the first column and then click the "Download Selected in PDF format (Zip Archive)" or the "Download Selected as Single PDF" button.

List of published and non-published patent-specific documents on the CPD .

If you have any difficulty accessing content, you can call the Client Service Centre at 1-866-997-1936 or send them an e-mail at CIPO Client Service Centre.

({010=All Documents, 020=As Filed, 030=As Open to Public Inspection, 040=At Issuance, 050=Examination, 060=Incoming Correspondence, 070=Miscellaneous, 080=Outgoing Correspondence, 090=Payment})


Document
Description 
Date
(yyyy-mm-dd) 
Number of pages   Size of Image (KB) 
Representative drawing 2001-01-22 1 10
Abstract 2000-09-28 1 53
Description 2000-09-28 14 568
Claims 2000-09-28 5 172
Drawings 2000-09-28 4 64
Reminder of maintenance fee due 2001-01-14 1 112
Notice of National Entry 2001-01-11 1 195
Courtesy - Certificate of registration (related document(s)) 2001-05-23 1 113
Courtesy - Abandonment Letter (Maintenance Fee) 2002-05-06 1 183
Correspondence 2001-01-11 1 15
PCT 2000-09-28 7 236